Here Is How You Can Invest In Marijuana StocksWhat is it about the cannabis industry that keeps investors searching for top marijuana stocks to buy? Cannabis started as one of the first waves of peace, love, and rebellion towards many cultural injustices. Today, those same principles are the foundation in spirit. But the evolution of legal cannabis changed the culture forever. In 2026, significant changes have occurred and continue to happen. We have a battle for who will take over, will it be corporate can ...

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - Aurora Cannabis Inc. reported a net revenue increase of C$7 million to C$94.2 million for the quarter, driven by the global medical cannabis and plant propagation segments [2] - The company is focusing on the higher-margin medical cannabis business, with revenue from this segment rising 12% to C$76.2 million, representing 81% of total revenue [2][4] - Adjusted gross margin improved to 62%, while adjusted EBITDA decreased by 5% year over year to C$18.5 million due to higher operating expenses [3] Financial Performance - The medical cannabis segment's growth was led by a 17% increase in international markets, particularly in Germany and Poland [2] - Management confirmed full year 2026 adjusted EBITDA guidance of C$52–57 million, despite a cautious outlook for the fourth quarter [3] - ACB's balance sheet is strong, with C$154 million in cash and no debt, and the company has filed for an at-the-market offering of up to C$100 million for additional capital flexibility [4] Strategic Focus - ACB is divesting from the less-profitable plant propagation business and exiting select Canadian consumer cannabis markets to focus on international medical opportunities [4] - Management anticipates fiscal year 2026 to be a record revenue year, with continued growth and margin expansion expected through fiscal year 2028 [5] - Despite top-line growth and improved margins, ACB's valuation remains discounted compared to peers and its historical performance, indicating potential for a rerating in 2026 [5]

Key Takeaways ACB topped Q3 earnings and revenue estimates, with sales rising 7% year over year to about $68 million.ACB's medical cannabis revenue grew roughly 20% over nine months, led by strength in Europe and Australia.ACB plans to exit certain Canadian consumer markets to improve margins despite near-term transition costs.Aurora Cannabis (ACB) recently reported its third-quarter results for fiscal 2026 (year ending March 2026). Both earnings and sales beat our consensus estimates.This Canada-based cann ...

Core Viewpoint - Aurora Cannabis Inc. reported financial results that were in line with expectations, showing revenue growth both year-over-year and quarter-over-quarter [1] Financial Performance - Revenue increased compared to the previous year and the previous quarter [1] - The company reported free cash flow but still incurred an overall net loss [1] Strategic Focus - Aurora Cannabis plans to divest its plant propagation segment to concentrate more on its core business areas [1]

PresentationTheunis Eloff Ladies and gentlemen, welcome to this 25th Annual General Meeting of Astral Foods Limited. Pleasure and welcome you. My name is Theunis Eloff, Chairman of the Board. And in terms of the memorandum of incorporation, I preside as Chairman. The Secretary informs me that the necessary quorum is present, and I declare this meeting properly constituted. I suggest that the notice convening this meeting, which has been circulated and a copy of which is before you be taken as read. Is that ...

Aurora reported consolidated adjusted gross margin of 62%, up 100 basis points year over year, while adjusted gross profit increased 6% to CAD 55.6 million. The medical cannabis segment posted an adjusted gross margin of 69%, which management attributed to the mix shift toward higher-margin international markets as well as sustainable cost reductions and operational efficiencies, including sourcing for Europe from Canada.CFO Simona King said total net revenue was CAD 94.2 million, supported by contributions ...

We are one of Canada's largest global medical cannabis companies. We are Canada's leading exporter of medical cannabis. And finally, we are a market leader in the three biggest nationally legal medical cannabis markets outside of Canada. Notably, about 90% of our annual manufacturing capacity is produced within Aurora's European and TGA GMP-certified facilities and is subject to very stringent international standards. These standards are only increasing, significantly limiting the number of market participa ...

Aurora Cannabis (NasdaqCM:ACB) Q3 2026 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsBrenna Cunnington - Equity Research AssociateDerek Lessard - Director of Equity ResearchKenric Tyghe - Director of Equity Research of Special SituationsKevin Niland - Director of Strategic Finance and Head of Investor RelationsMiguel Martin - Executive Chairman and CEOPablo Zuanic - Founder and Managing PartnerSimona King - CFOConference Call ParticipantsBill Kirk - Managing Director and Senior Research An ...

Aurora Cannabis (NasdaqCM:ACB) Q3 2026 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsBrenna Cunnington - Equity Research AssociateDerek Lessard - Director of Equity ResearchKenric Tyghe - Director of Equity Research of Special SituationsKevin Niland - Director of Strategic Finance and Head of Investor RelationsMiguel Martin - Executive Chairman and CEOPablo Zuanic - Founder and Managing PartnerSimona King - CFOConference Call ParticipantsBill Kirk - Managing Director and Senior Research An ...